Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Swetha Thambireddy"'
Autor:
Esther P. Jane, Daniel R. Premkumar, Dhivyaa Rajasundaram, Swetha Thambireddy, Matthew C. Reslink, Sameer Agnihotri, Ian F. Pollack
Publikováno v:
Molecular Oncology, Vol 16, Iss 1, Pp 219-249 (2022)
Acquired resistance to conventional chemotherapeutic agents limits their effectiveness and can cause cancer treatment to fail. Because enzymes in the aurora kinase family are vital regulators of several mitotic events, we reasoned that targeting thes
Externí odkaz:
https://doaj.org/article/3cd2313c7d254eaab053411dfc37ad9e
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental File 2: Genes common to all resistant U87 cell lines compared to drug naive control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01f7077cb773aa084ad299586693d6ac
https://doi.org/10.1158/1541-7786.22514064
https://doi.org/10.1158/1541-7786.22514064
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental File 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa56ff9776a3bec668f53c229ce01fd5
https://doi.org/10.1158/1541-7786.22514055
https://doi.org/10.1158/1541-7786.22514055
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental Figure 4. Volcano plot representing differentially expressed genes for U87 naive versus resistant cells with a minimum of a 1.5-fold change, P-value < 0.05 and FDR < 0.10 between control and A.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5fc6e09dc92a9d4ceb7c99fb2ce7fac
https://doi.org/10.1158/1541-7786.22514082
https://doi.org/10.1158/1541-7786.22514082
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental Figure 1. Schematic of the approach taken to achieve drug resistance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e28665fbf234b5a3b0cd1d5862b6aa
https://doi.org/10.1158/1541-7786.22514091.v1
https://doi.org/10.1158/1541-7786.22514091.v1
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental Figure 3. Drug naive U87 or panobinostat-resistant, bortezomib-resistant, or panobinostat and bortezomib-resistant (P + B) cells were cotreated with panobinostat (25 nmol/L) plus bortezomib (2.5 nmol/L) for 24 h.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779a7a10817c7974c156afe0f62f268a
https://doi.org/10.1158/1541-7786.22514085.v1
https://doi.org/10.1158/1541-7786.22514085.v1
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental Figure Legends 1-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cb44e67716c3813f1ebf9c6382161b0
https://doi.org/10.1158/1541-7786.22514070.v1
https://doi.org/10.1158/1541-7786.22514070.v1
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental Figure 6. A. Drug naive and panobinostat and bortezomib-resistant (P + B) U87 cells were treated with gefitinib (2 µmol/L), enzastaurin (2 µmol/L), dasatinib (0.1 µmol/L), dinaciclib (0.18 µmol/L), PI 103 (1 µmol/L), PD 0325901 (2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25d68125876a120fb95a0a6c9abaa08
https://doi.org/10.1158/1541-7786.22514076.v1
https://doi.org/10.1158/1541-7786.22514076.v1
Autor:
Ian F. Pollack, Andrew M. Stern, Mark E. Schurdak, D. Lansing Taylor, Ansuman Chattopadhyay, Max I. Myers, Stephen C. Mack, Kelsey C. Bertrand, Sameer Agnihotri, Brian Golbourn, Swetha Thambireddy, Daniel R. Premkumar, Esther P. Jane
Supplemental Figure 7. Bar graph showing QPRT mRNA expression levels (absolute value) between drug naive and panobinostat + bortezomib resistant DIPG 007, SJG 2 and U87 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6747897afe7ffa585c19f6a6f3e0f5f0
https://doi.org/10.1158/1541-7786.22514073.v1
https://doi.org/10.1158/1541-7786.22514073.v1
Autor:
Kelsey C. Bertrand, Ansuman Chattopadhyay, Max I. Myers, Sameer Agnihotri, D. Lansing Taylor, Mark E. Schurdak, Andrew M. Stern, Brian Golbourn, Esther P. Jane, Daniel R. Premkumar, Ian F. Pollack, Swetha Thambireddy, Stephen C. Mack
Publikováno v:
Molecular Cancer Research. 18:1004-1017
To improve therapeutic responses in patients with glioma, new combination therapies that exploit a mechanistic understanding of the inevitable emergence of drug resistance are needed. Intratumoral heterogeneity enables a low barrier to resistance in